14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Biogen (NASDAQ:BIIB), which obtained regulatory and commercial rights to Tofidence from the Chinese biotech Bio-Thera Solutions in 2021, launched the monoclonal antibody three years later as the ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and ...

Every investor in Biogen Inc. (NASDAQ:BIIB) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 90% ownership.

Biogen's results beat estimates on strength in rare disease drugs Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset ...